NOD2/CARD15 Mutations correlate with severe pouchitis after ileal pouch-anal anastomosis

Diseases of the Colon and Rectum

Volumn 53, Issue 11, 2010, Pages 1487-1494

  Sehgal, Rishabh ^a   Berg, Arthur ^a   Hegarty, John P ^a   Kelly, Ashley A ^a   Lin, Zhenwu ^a   Poritz, Lisa S ^a   Koltun, Walter A ^a  

^a PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

Author keywords

Classification; Crohn's disease; Genetics; Inflammatory bowel disease; NOD2 CARD15; Pouchitis; Ulcerative colitis

Indexed keywords

ANTIBIOTIC AGENT; CASPASE RECRUITMENT DOMAIN PROTEIN 15; NOD2 PROTEIN, HUMAN;

ANUS FISTULA; ARTICLE; COLITIS; COMPARATIVE STUDY; CONTROLLED STUDY; CROHN DISEASE; DISEASE ASSOCIATION; ENTERITIS; FEMALE; GENOTYPE; GRANULOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; ILEITIS; ILEOANAL ANASTOMOSIS; ILEOSTOMY; ILEUM POUCH; MAJOR CLINICAL STUDY; MALE; MUTATION; MUTATIONAL ANALYSIS; POLYMERASE CHAIN REACTION; PREOPERATIVE EVALUATION; RETROSPECTIVE STUDY; SINGLE NUCLEOTIDE POLYMORPHISM; YATES CONTINUITY CORRECTION; ANASTOMOSIS; CASE CONTROL STUDY; CHI SQUARE DISTRIBUTION; COLON POUCH; GENETICS; HOSPITALIZATION; POSTOPERATIVE COMPLICATION; PROCTOCOLECTOMY; ULCERATIVE COLITIS;

ANASTOMOSIS, SURGICAL; CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; COLITIS, ULCERATIVE; COLONIC POUCHES; FEMALE; GENOTYPE; HUMANS; MALE; MUTATION; NOD2 SIGNALING ADAPTOR PROTEIN; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE; POSTOPERATIVE COMPLICATIONS; POUCHITIS; PROCTOCOLECTOMY, RESTORATIVE; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX;

EID: 78349269077     PISSN: 00123706     EISSN: 15300358     Source Type: Journal    
DOI: 10.1007/DCR.0b013e3181f22635     Document Type: Article

References (46)

1. Shen B, Fazio VW, Remzi FH, Lashner BA. Clinical approach to diseases of ileal pouch-anal anastomosis. Am J Gastroenterol. 2005;100:2796-2807.
2. Shen B, Patel S, Lian L. Natural history of Crohn's disease in patients who underwent intentional restorative proctocolectomy with ileal pouch-anal anastomosis. Aliment Pharmacol Ther. 2010;31:745-753.
3. Hugot JP, Chamaillard M, Zouali H, et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature. 2001;411:599-603.
4. Ogura Y, Bonen DK, Inohara N, et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature. 2001;411:603-606.
5. Shen B. Diagnosis and treatment of patients with pouchitis. Drugs. 2003;63:453-461.
6. Zhang WJ, Thompson JL, Chorney MJ, Koltun WA. Phenotyping of IL4-induced nuclear Stat6 activity in humans: quantitation after gel shift assay using immortalized cell lines. Oncol Rep. 2003;10:1281-1288.
7. Shen B, Fazio VW, Remzi FH, et al. Comprehensive evaluation of inflammatory and noninflammatory sequelae ofileal pouchanal anastomoses. Am J Gastroenterol. 2005;100:93-101.
8. Papadakis KA, Treyzon L, Abreu MT, Fleshner PR, Targan SR, Vasiliauskas EA. Infliximab in the treatment of medically refractory indeterminate colitis. Aliment Pharmacol Ther. 2003;18: 741-747.
9. Shen B, Remzi FH, Lavery IC, et al. Administration of adalimumab in the treatment of Crohn's disease of the ileal pouch. Aliment Pharmacol Ther. 2009;29:519-526.
10. Coffey JC, Rowan F, Burke J, Dochery NG, Kirwan WO, O'Connell PR. Pathogenesis of and unifying hypothesis for idiopathic pouchitis. Am J Gastroenterol. 2009;104:1013-1023.
11. Meier CB, Hegazi RA, Aisenberg J, et al. Innate immune receptor genetic polymorphisms in pouchitis: is CARD15 a susceptibility factor? Inflamm Bowel Dis. 2005;11:965-971.
12. Mimura T, Rizzello F, Helwig U, et al. Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis. Gut. 2004;53:108-114.
13. Gionchetti P, Rizzello F, Venturi A, et al. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology. 2000; 119:305-309.
14. Wellcome Trust Case Control Consortium. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature. 2007;447:661-678.
15. Barrett JC, Hansoul S, Nicolae DL, et al. Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. Nat Genet. 2008;40:955-962.
16. Duerr RH, Taylor KD, Brant SR, et al. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science. 2006;314:1461-1463.
17. Fisher SA, Tremelling M, Anderson CA, et al. Genetic determinants of ulcerative colitis include the ECM1 locus and five loci implicated in Crohn's disease. Nat Genet. 2008;40:710-712.
18. Franke A, Balschun T, Karlsen TH, et al. Sequence variants in IL10, ARPC2 and multiple other loci contribute to ulcerative colitis susceptibility. Nat Genet. 2008;40:1319-1323.
19. Hampe J, Franke A, Rosenstiel P, et al. A genome-wide association scan of nonsynonymous SNPs identifies a susceptibility variant for Crohn disease in ATG16L1. Nat Genet. 2007;39:207-211. (Pubitemid 46184351)
20. Libioulle C, Louis E, Hansoul S, et al. Novel Crohn disease locus identified by genome-wide association maps to a gene desert on 5p13.1 and modulates expression of PTGER4. PLoS Genet. 2007; 3:e58.
21. Parkes M, Barrett JC, Prescott NJ, et al. Sequence variants in the autophagy gene IRGM and multiple other replicating loci contribute to Crohn's disease susceptibility. Nat Genet. 2007;39: 830-832.
22. Silverberg MS, Cho JH, Rioux JD, et al. Ulcerative colitis-risk loci on chromosomes 1p36 and 12q15 found by genome-wide association study. Nat Genet. 2009;41:216-220.
23. Mathew CG. New links to the pathogenesis of Crohn disease provided by genome-wide association scans. Nat Rev Genet. 2008;9:9-14.
24. Noomen CG, Hommes DW, Fidder HH. Update on genetics in inflammatory disease. Best Pract Res Clin Gastroenterol. 2009;23: 233-243.
25. Huebner C, Petermann I, Lam WJ, Shelling AN, Ferguson LR. Characterization of single-nucleotide polymorphisms relevant to inflammatory bowel disease in commonly used gastrointestinal cell lines. Inflamm Bowel Dis. 2010;16:282-295.
26. Scherr R, Essers J, Hakonarson H, Kugathasan S. Genetic determinants of pediatric inflammatory bowel disease: is age of onset genetically determined? Dig Dis. 2009;27:236-239.
27. Nakagome S, Takeyama Y, Mano S, et al. Population-specific susceptibility to Crohn's disease and ulcerative colitis: dominant and recessive relative risks in the Japanese population. Ann Hum Genet. 2010;74:126-136.
28. McGovern DP, Gardet A, Törkvist L, et al. Genome-wide association identifies multiple ulcerative colitis susceptibility loci. Nat Genet. 2010;42:332-337.
29. Rogler G. The importance of gut microbiota in mediating the effect of NOD2 defects in inflammatory bowel disease. Gut. 2010;59:153-154.
30. Brain O, Allan P, Simmons A. NOD2-mediated autophagy and Crohn disease. Autophagy. 2010;6:412-414.
31. Hugot JP, Zaccaria I, Cavanaugh J, et al. Prevalence of CARD15/NOD2 mutations in Caucasian healthy people. Am J Gastroen- terol. 2007;102:1259-1267.
32. Hampe J, Cuthbert A, Croucher PJ, et al. Association between insertion mutation in NOD2 gene and Crohn's disease in German and British populations. Lancet. 2001;357:1925-1928.
33. Abreu MT, Taylor KD, Lin YC, et al. Mutations in NOD2 are associated with fibrostenosing disease in patients with Crohn's disease. Gastroenterology. 2002;123:679-688.
34. Ahmad T, Armuzzi A, Bunce M, et al. The molecular classification ofthe clinical manifestations ofCrohn's disease. Gastroenterology. 2002;122:854-866.
35. Cuthbert AP, Fisher SA, Mirza MM, et al. The contribution of NOD2 gene mutations to the risk and site ofdisease in inflammatory bowel disease. Gastroenterology. 2002;122:867-874.
36. Hampe J, Grebe J, Nikolaus S, et al. Association of NOD2 (CARD 15) genotype with clinical course of Crohn's disease: a cohort study. Lancet. 2002;359:1661-1665.
37. Lesage S, Zouali H, Cézard JP, et al. CARD15/NOD2 mutational analysis and genotype-phenotype correlation in 612 patients with inflammatory bowel disease. Am J Hum Genet. 2002;70: 845-857.
38. Vermeire S, Wild G, Kocher K, et al. CARD15 genetic variation in a Quebec population: prevalence, genotype-phenotype relationship, and haplotype structure. Am J Hum Genet. 2002;71: 74-83.
39. Oostenbrug LE, Nolte IM, Oosterom E, et al. CARD15 in inflammatory bowel disease and Crohn's disease phenotypes: an association study and pooled analysis. Dig Liver Dis. 2006;38: 834-845.
40. Heresbach D, Gicquel-Douabin V, Birebent B, et al. NOD2/CARD15 gene polymorphisms in Crohn's disease: a genotypephenotype analysis. Eur J Gastroenterol Hepatol. 2004;16:55-62.
41. Joyce MR, Fazio VW. Can ileal pouch anal anastomosis be used in Crohn's disease? Adv Surg. 2009;43:111-137.
42. Targan SR. The utility of ANCA and ASCA in inflammatory bowel disease. Inflamm Bowel Dis. 1999;5:61-63.
43. Fleshner PR, Vasiliauskas EA, Kam LY, et al. High level perinuclear antineutrophil cytoplasmic antibody (pANCA) in ulcerative colitis patients before colectomy predicts the development of chronic pouchitis after ileal pouch-anal anastomosis. Gut. 2001;49:671-677.
44. Sandborn WJ, Landers CJ, Tremaine WJ, Targan SR. Antineutrophil cytoplasmic antibody correlates with chronic pouchitis after ileal pouch-anal anastomosis. Am J Gastroenterol. 1995;90: 740-747.
45. Aisenberg J, Legnani PE, Nilubol N, et al. Are pANCA, ASCA, or cytokine gene polymorphisms associated with pouchitis? Longterm follow-up in 102 ulcerative colitis patients. Am J Gastroenterol. 2004;99:432-441.
46. Yasuda N, Thomas P, Ellis H, Herbst F, Nicholls J, Ciclitira P. Perinuclear anti-neutrophil cytoplasmic antibodies in ulcerative colitis after restorative proctocolectomy do not correlate with the presence of pouchitis. Scand J Gastroenterol. 1998;33:509-513.